A 61-year-old Japanese man was referred to our hospital in 2002 due to severe pancytopenia. Bone marrow and peripheral blood findings indicated he had severe aplastic anemia (AA). A whole-body CT scan and Ga scintigraphy revealed no abnormal findings. Antithymocyte globulin and cyclosporine A (CyA) were administered and he got transfusion independently. In September 2004, he complained of abdominal fullness and a skin eruption in the lower abdomen. An abdominal CT revealed a spleen mass and lymphoadenopathy of the pancreas head. Splenectomy was done, and he was diagnosed with a diffuse large B cell lymphoma (DLBCL) of the spleen and skin. His karyotype was associated with t(14; 18). CyA was stopped, all lesions disappeared, and then his AA relapsed. In January 2007, antithymocyte globulin/CyA was readministered. In May 2007, he complained of acute swelling in his right thigh. A biopsy from the tumor revealed DLBCL. CyA was stopped again, yet the lymphoma did not regress. He was given R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisolone), followed by 5 cycles of R-VP (rituximab, vincristine, prednisolone) and radiation therapy, resulting in a partial remission. We report DLBCL after immunosuppressive therapy for AA. Although this is a rare complication, it should be considered before beginning immunosuppressive therapy.

Keywords:
Aplastic anemia, Immunosuppressive therapy, Lymphoproliferative disorder
1.
Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A, Omine M, Mizoguchi H: Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporine A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007;110:1756–1761.
2.
Young NS, Calado R, Scheinberg P: Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509–2519.
3.
Frickhofen N, Rosenfeld SJ: Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol 2000;37:56–68.
4.
Tichelli A, Gratwohl A, Wursch A, Nissen C, Speck B: Late haematological complications in severe aplastic anaemia. Br J Haematol 1988;69:413–418.
5.
Socié G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, McCann SR, Frickhofen NF, Veer-Korthof EV, Gluckman E: Malignant tumors occurring after treatmet of aplastic anemia. N Engl J Med 1993;329:1152–1157.
6.
Socié G, Rosenfeld S, Fickhofen N, Gluckman E, Tichelli A: Late clonal disease of treated aplastic anemia. Semin Hematol 2000;37:91–101.
7.
Paquett R, Tebyani N, Frane M, Ireland P, Ho WG, Champlin RE, Nimer SD: Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantarion. Blood 1995;85:283–290.
8.
Ruiz-Argüelles G, Gomez-Rangel JD: Long-term results of the immunosuppressive treatment of patients with severe acquired aplastic anemia: a single institution study. Acta Haematol 2003:110;184–187.
9.
Dorr V, Dolittle G, Woodroof J: First report of a B cell lymphoproiferative disorder arising in a patient treated with immune suppressants for severe aplastic anemia. Am J Hematol 1996;52:108–113.
10.
Sarangi JN, Kashyap R, Choudhry VP, Mishra DK, Saxena R, Gurbaxani S, Bhargava M: Severe aplastic anemia evolving into T cell acute lymphoblastic leuekmia. Eur J Haematol 1999;63:269–271.
11.
Takeuchi M, Soda R, Kimura F, Lai M, Ueda Y: Philadelpha chromosome positive acute lymphocytic leukemia arising from aplastic anemia. Am J Hematol 2000;63:161–162.
12.
Hirose Y, Masaki Y, Ebata K, Okada J, Kim C, Ogawa N, Wano Y, Sugai S: T-cell type acute lymphoblastic leukemia following cyclosporin A therapy for aplastic anemia. Int J Hematol 2000;73:226–229.
13.
Doney K, Leisenreing W, Storb R, Appelbaum FR: Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med 1997;126:107–115.
14.
Führer M, Burdach S, Ebell W, Gadner H, Haas R, Harbott J, Janka-Schaub G, Klingebiel T, Kremens B, Niemeyer C, Rampf U, Reiter A, Ritter J, Schultz, A, Walther U, Zeidler C, Bender-Gotze C: Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. Klin Padiatr 1998;210:173–179.
15.
Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, Gabbas A, Dufour C, Arcese W, Testi G, Broccia G, Cartotenuto M, Coser P, Barbui T, Leoni P, Ferster A: Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood 2000;95:1931–1934.
16.
Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, Sugita K, Yabe H, Ohara A, Tsukimoto I: Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96:2049–2054.
17.
Ahn M, Choi J, Lee Y, Choi I, Kim I, Y S, Park S, Kim V, Suh C, Son HJ, Jung C, Lee J, Sung J, Im S, Oh D, Jing S, Yoon H, Cho K, Lee J, YuhY, Kim S, Ki M: Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial. Int J Hematol 2003;78:133–138.
18.
Frickhofen N, Heimple H, Kaltwasser JP, Schrezenmeier H: Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236–1242.
19.
Rosenfeld S, Follmann D, Nunez O, Young NS: Antithymocyte globulin and cyclosporine for severe aplastic anemia. JAMA 2003;289:1130–1135.
20.
Locasciulli A, Bruno B, Rambaldi A, Saracco P, Dufour C, Finelli C, Sica S, Varotto S, Arcese W, Locatelli F, Soligo D, Bacigalupo A: Treatment of severe aplastic anemia with antilymphocyte globulin cyclosporine and two different granulocyte colony-stimulating factor regiments: a GITMO prospective randomized study. Haematologica 2004;89:1054–1061.
21.
Scheinberg P, Nunez O, Wu C, Young N: Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, cyclosporin and mycophenoate mofetil. Br J Haematol 2006;133:606–611.
22.
Dinçol G, Aktan M, Diz-Küçükkaya R, Yavuz S, Nalçaci M, Öztürk S, Palanduy S, Dogan O, Agan M: Treatment of acquired severe aplastic anemia with antilymphocyte globulin, cyclosporine A, methyprednisolone, and granulocyte colony-stimulating factor. Am J Hematol 2007;82:783–786.
23.
Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A: Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin’s lymphoma. N Engl J Med 1982;307:1231–1236.
24.
Kramer MHH, Hermans J, Wijburg E, Phillippo K, Geelen E, van Krieken JHJM, De Jong D, Maartense E, Schuuring E, Klui PM: Cllinical relevance of BCL-2, BCL-6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998;92:3152–3162.
25.
Basecke J, Griesinge F, Trumper L, Brittinger G: Leukemia- and lymphoma-associated genetic aberrations in healthy individuals. Ann Hematol 2002;81:64–75.
26.
Schueler F, Hirt C, Dolken G: Chromosomal translocation t(14 ;18) in healthy individuals. Semin Cancer Biol 2003;13:203–209.
27.
Schmitt C, Balogh B, Grundt A, Buchholtz C, Leo A, Benner A, Hensel M, Ho AD, Leo E: The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity. Leuk Res 2006;30:745–750.
28.
Lim ST, Levine AM: Recent advances in acquired immunodeficiency syndorome (AIDS)-related lymphoma. Ca Cancer J Clin 2005;55:229–241.
29.
Bakker NA, van Imhoff GW: Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention? Haematologica 2007;92:1447–1450.
30.
Kamel OW, Van de Rijin M, Weiss LM, Del Zopo GJ, Hench PK, Robbins BA, Montgomery PG, Warnke RA, Dorfman RF: Reversible lymphomas associated with Epstein-Barr occurring during methotrexate therapy fro rheumatoid arthritis and dermatomyositis. N Eng J Med 1993;328:1317–1321.
31.
Hoshida Y, Xu J, Fujita S, Nakamichi I, Ikeda J, Tomita Y, Naktsuka S, Tamaru J, Iizuka A, Takeuchi T, Aozasa K: Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007;34:322–331.
32.
Shimoyama Y, Yamamoto K, Asano N, Oyama T, Kinoshita T, Nakamura S: Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci 2008;99:1085–1091.
33.
Scheinberg P, Fischer SH, Nunez O, Wu CO, Sloand EM, Cohen JI, Youn NS, Barrett AJ: Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007;109:3219–3224.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.